TGF-β / Smad Signaling

The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
-
B1294 SR-3677Target: ROCKSummary: Rho Kinase (ROCK-II) inhibitor -
B1287 Ro 31-8220Target: PKCSummary: pan-PKC inhibitor -
B3688 ML347Target: BMP and Other Activin ReceptorsSummary: BMP receptor inhibitor,potent and selective -
A8607 PPY ATarget: Abl kinasesSummary: Abl kinases inhibitor -
B1293 Y-2763237 CitationTarget: ROCKSummary: ROCK inhibitor -
A8830 ZIP (SCRAMBLED)Summary: PKMζ inhibitor -
B3687 LDN-212854Summary: BMP receptor inhibitor,potent and selective -
A8606 PD 180970Summary: P210bcr/abl tyrosine kinase inhibitor -
A8801 ICP 103Summary: Protein kinase inhibitor -
B1176 Y-39983 dihydrochlorideSummary: ROCK family inhibitor
